Last reviewed · How we verify

Cinacalcet HCl

Montefiore Medical Center · FDA-approved active Small molecule Quality 5/100

Cinacalcet HCl is a Small molecule drug developed by Montefiore Medical Center. It is currently FDA-approved. Also known as: Mimpara®, Sensipar, Mimpara, Regpara, Sensipar®.

At a glance

Generic nameCinacalcet HCl
Also known asMimpara®, Sensipar, Mimpara, Regpara, Sensipar®
SponsorMontefiore Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cinacalcet HCl

What is Cinacalcet HCl?

Cinacalcet HCl is a Small molecule drug developed by Montefiore Medical Center.

Who makes Cinacalcet HCl?

Cinacalcet HCl is developed and marketed by Montefiore Medical Center (see full Montefiore Medical Center pipeline at /company/montefiore-medical-center).

Is Cinacalcet HCl also known as anything else?

Cinacalcet HCl is also known as Mimpara®, Sensipar, Mimpara, Regpara, Sensipar®.

What development phase is Cinacalcet HCl in?

Cinacalcet HCl is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing